<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04426240</url>
  </required_header>
  <id_info>
    <org_study_id>2019-11-203</org_study_id>
    <nct_id>NCT04426240</nct_id>
  </id_info>
  <brief_title>The Effect of Cyclosporin Before Cataract Surgery</brief_title>
  <official_title>A Comparative Study of Use of Cyclosporin Eye Before Cataract Surgery for the Prevention of Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of cyclosporine eye drop before cataract surgery for the prevention of
      post cataract surgery dry eye syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 11, 2020</start_date>
  <completion_date type="Anticipated">June 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 11, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal florescence staining score</measure>
    <time_frame>1 month</time_frame>
    <description>Standardized corneal staining score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tear break-up time</measure>
    <time_frame>1 month</time_frame>
    <description>Time to break tear film</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer test</measure>
    <time_frame>1 montn</time_frame>
    <description>Tear secretion test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Cyclosporine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject who use cyclosporine and hyaluronate artificial tear 1 month before cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-Cyclosporine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subject who use only hyaluronate eye drop 1 month before cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine microemulsion</intervention_name>
    <description>Intervention group receives topical cyclosporine dry eye treatment before cataract surgery</description>
    <arm_group_label>Cyclosporine</arm_group_label>
    <other_name>Cyporin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 21+ adult men and women

          2. Those who are scheduled to undergo cataract surgery due to a diagnosis of cataract

          3. Corneal fluorescein staining score (Oxford) is II or less

          4. Preoperative MMP-9 positive

          5. Those who have not used the trial and the test (cyclosporine) for at least 1 month
             before surgery.

          6. Those who have voluntarily written consent to participate in this clinical trial

        Exclusion Criteria

          1. Those who have used systemic or topical cyclosporine within 4 weeks

          2. Use of eye drops for more than 4 weeks (disorders, allergies, eye inflammation /
             infection, etc.) other than the current dry eye syndromes

          3. Patients who have systemic or ocular disorders or conditions (eye surgery, trauma,
             disease) that can influence the results of this trial.

          4. Abnormal eyelid function

          5. An eye disease that can impair the function of the corneal sensation: herpes
             keratopathy, conjunctival wounds due to scarring conjunctivitis, pterygium,
             pinguecula, diabetic keratitis, keratoconus , corneal transplant status

          6. Patients with active eye infections

          7. Patients with conflicts with this clinical trial

          8. Pregnant and lactating mothers

          9. Patients who are determined to be inappropriate by other investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae-Young Chung</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tae-Young Chung</last_name>
    <phone>+82-2-3410-2331</phone>
    <email>taeyoung15.chung@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dong Hui Lim</last_name>
    <phone>+82-2-3410-6503</phone>
    <email>ldhlse@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>tae-young chung</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

